Jim Cramer has his eyes on an energy asset sale that could make major waves on Wall Street. » Read More
By: Dan Mangan
There are fewer than 350 Obamacare customers who remain at risk of having no coverage options next year. » Read More
By: Robert Ferris
A Tesla Model X and Model S, both P100D models with Ludicrous, edged out the Lamborghini in a quarter-mile drag race held by Drag Times. » Read More
The plaintiff claimed that the company's baby powder causes ovarian cancer when applied regularly for feminine hygiene. » Read More
Medical device maker Medtronic reported a 9.4 percent increase in quarterly profit on Tuesday, driven by strong demand for its heart and vascular devices.
Martin Shkreli was convicted of three criminal counts but acquitted of five others. He faces possible prison time.
Collaborative relationships with hospitals across the globe are improving patient outcomes and operational efficiencies.
Andy Page, formerly president of Google-backed 23andMe, is joining Livongo, a chronic disease management start-up, as its president and CFO.
Drugmaker Hikma's US unit reportedly raised the price of a common diarrhea drug by more than 400 percent.
State health insurance regulators expect that the fate of key health insurance subsidies will remain in limbo past key deadlines next month.
More Americans think the government has an obligation to ensure health care coverage to all citizens, Vox reports.
Glenview Capital Management, Tenet Healthcare's largest shareholder, is pulling its two representatives off the hospital company's board.
The settlement came after an unusual lawsuit by Sanofi, a competitor to Mylan, which alleged anti-competitive tactics.
Mandi Bishop was invited to the Apple, Aetna event. She shares her recollections with CNBC.
The FDA approved Pfizer's rare blood cancer drug, Besponsa, with a boxed warning.
U.S. Representatives Elijah Cummings and Peter Welch sent the letters to seven drugmakers.
JPMorgan's research team shared its top biotech stock picks coming out of the second-quarter earnings season.
Mylan said 10 months ago it reached a deal resolving claims it misclassified the EpiPen as a generic.
Color Genomics raised its most recent round from General Catalyst, CRV and Emerson Collective's Laurene Powell Jobs, among others.
Mark Bertoloni's memo came to light hours after an exodus of CEOs from White House business councils spurred Trump to disband those groups.
Get the best of CNBC in your inbox